Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1071-1076

  Reckzeh, B ^a   Merte, H ^a   Pfluger K H ^a   Pfab, R ^a   Wolf, M ^a   Havemann, K ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; COTRIMOXAZOLE; DEXAMETHASONE; DIMETINDENE; FLUCONAZOLE; ITRACONAZOLE; PACLITAXEL; RANITIDINE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; HEMATOLOGICAL PARAMETERS; HUMAN; INFECTIOUS COMPLICATION; INTERSTITIAL PNEUMONIA; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0029865284     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1071     Document Type: Article

References (18)

1. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 277:665-667, 1979
2. Schiff PB, Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561-1565, 1980
3. Milas L, Hunter NR, Mason KA, et al: Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res 54:3506-3510, 1994
4. Steren A, Sevin BU, Perras J: Taxol sensitizes human ovarian cancer cells to radiation. Gynecol Oncol 48:252-258, 1993
5. Tishler RB, Geard CR, Hall EJ: Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52:3495-3497, 1992
6. Choy H, Akerley W, Safran H, et al: Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 12:2682-2686, 1994
7. Havemann K, Wolf M, Goerg C, et al: Paclitaxel and simultaneous radiation in the treatment of stage IIIa/b non-small-cell lung cancer (NSCLC). Semin Oncol 22:19-22, 1995 (suppl 14)
8. Rowinsky EK, Donehower RC: Drug therapy: Paclitaxel (Taxol). N Engl J Med 332:1004-1014, 1995
9. Havemann K, Wolf M, Görg C, et al: Preclinical and clinical experience with cisplatin and carboplatin and simultaneous radiation in non-small cell lung cancer. Ann Oncol 3:S33-S37, 1992 (suppl)
10. Morgan GW, Breit SN: Radiation and the lung: A reevaluation of the mechanisms mediating pulmonary injury. Int J Radiat Oncol Biol Phys 31:361-369, 1995
11. Hellmann S, Quist M, Basler G, et al: Hematological safety profile of Taxol (paclitaxel) in patients with metastatic breast cancer and ovarian cancer. Blood 84:590a, 1994 (abstr 2346)
12. Wiernik PH, Schwartz EL, Strauman JJ, et al: Phase I clinical and pharmacokinetic study of Taxol. Cancer Res 47:2486-2493, 1987
13. National Cancer Institute Clinical Brochure: Taxol. Bethesda, MD, NCI, 1983, pp 6-12
14. Stuck AE, Minder CE, Frey FJ: Risk of infectious complications in patients taking glucocorticoids. Rev Infect Dis 11:954-963, 1989
15. Mackall CL, Fleisher TA, Brown MR, et al: Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 84:2221-2228, 1994
16. Bergmann L, Fenchel K, Jahn B, et al: Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 4:371-375, 1993
17. Wijermans PW, Gerrits WBJ, Haak HL: Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 50:292-296, 1993
18. Betticher DC, Fey MF, von Rohr A, et al: High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic acute leukemias. Ann Oncol 5:57-64, 1994